Cerqueira Patrícia M G, Silva Felipe T B Gaspar C da, Carricondo Pedro Carlos, Olivalves Edilberto, Hirata Carlos Eduardo, Yamamoto Joyce Hisae
Departament of Ophthalmology, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brasil.
Arq Bras Oftalmol. 2017 Mar-Apr;80(2):104-107. doi: 10.5935/0004-2749.20170025.
: To evaluate the outcomes of phacoemulsification with intraocular lens (IOL) implantation in eyes with uveitis.
: Consecutive patients with uveitis and cataracts who had phacoemulsification and acrylic IOL implantation during 2007-2012 were evaluated for visual outcomes, etiology, and complications. Inflammation was controlled for at least 3 months before surgery, and oral prednisone (0.5 mg/kg/day) was administered to patients with non-infectious uveitis.
: This study investigated 45 eyes in 38 patients with a mean age of 52 ± 12.5 years. The most common etiologies among non-infectious causes (n=32; 73.3%) were Vogt-Koyanagi-Harada disease (n=9), Fuchs heterochromic iridocyclitis (n=4), and sympathetic ophthalmia (n=3). Four cases were idiopathic. Among infectious cases (n=13; 28.9%), the most common causes were toxoplasmosis (n=6) and presumed ocular tuberculosis (n=4). An acrylic IOL was implanted in-the-bag in all cases. After 1-year follow-up, an improvement in visual acuity of two or more lines was observed in 38 eyes (84.4%), and 28 eyes (62.2%) achieved a postoperative visual acuity of ≥0.5. Posterior capsule opacification was observed in 10 eyes (22.2%). Persistent postoperative inflammation (of >6 months) was observed in seven eyes (15.5%) and recurrence occurred in four eyes (8.8%). IOL was explanted in one eye. Intraocular hypertension was observed in six eyes (13.3%).
: Phacoemulsification with IOL implantation improved vision in most patients with coexisting cataracts and uveitis. Good preoperative and postoperative control of inflammation plays an important role in achieving favorable visual outcomes. Furthermore, the final visual outcome depends on the posterior segment status.
评估葡萄膜炎患者行白内障超声乳化吸除联合人工晶状体(IOL)植入术的效果。
对2007年至2012年期间连续接受白内障超声乳化吸除联合丙烯酸酯IOL植入术的葡萄膜炎合并白内障患者的视力结果、病因及并发症进行评估。术前炎症控制至少3个月,非感染性葡萄膜炎患者口服泼尼松(0.5mg/kg/天)。
本研究纳入38例患者的45只眼,平均年龄52±12.5岁。非感染性病因(n = 32;73.3%)中最常见的是伏格特-小柳-原田病(n = 9)、富克斯异色性虹膜睫状体炎(n = 4)和交感性眼炎(n = 3)。4例为特发性。感染性病例(n = 13;28.9%)中,最常见的病因是弓形虫病(n = 6)和疑似眼结核(n = 4)。所有病例均行囊袋内丙烯酸酯IOL植入。随访1年后,38只眼(84.4%)视力提高两行或更多行,28只眼(62.2%)术后视力≥0.5。10只眼(22.2%)出现后囊膜混浊。7只眼(15.5%)术后炎症持续(>6个月),4只眼(8.8%)复发。1只眼的IOL被取出。6只眼(13.3%)出现眼压升高。
白内障超声乳化吸除联合IOL植入术可改善大多数合并白内障和葡萄膜炎患者的视力。术前和术后良好的炎症控制对获得良好的视力结果起重要作用。此外,最终视力结果取决于眼后段情况。